References
- Klysner R, Butler B, Vilmar T, Bech P. Empirical versus prospective pharmacokinetic dosing of perphenazine in schizo-phrenic and acute paranoid disorders. Nord Psykiatr Tidsskr 1986; 40:473–7.
- Apiquian R, Fresan A, Herrera K, Ulloa RE, Loyzaga C, de la Fuente-Sandoval C, et al. Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. Int J Neuropsychopharmacol 2003;6:403–8.
- Gjerris A, Bech P, Broen-Christensen C, Geisler A, Klysner R, Rafaelsen OJ. Haloperidol plasma levels in relations to antimanic effect. In: Usdin E, Dahl S, Gram LF, Lingjxrde O, editors. Clinical pharmacological psychiatry. London: MacMillan Press; 1980. p. 227–32.
- Hansen LB, Larsen NE, Gullmann N. Dose-response relation-ships of perphenazine in the treatment of acute psychosis. Psychopharmacology 1982;78:112–5.
- Hansen LB, Larsen NE, Vestergaard P. Plasma levels of perphe-nazine (TrilafonR) related to development of extra-pyramidal side effects. Psychopharmacology 1981;74:306–9.
- Hansen LB, Larsen NE. Plasma monitoring of perfenazine to guide for antipsychotic effect. Nord Psykiatr Tidsskr 1986;40: 467–71.
- Hals PA, Hall H, Dahl SG. Phenothiazine drug metabolites: dopamine D2 receptor, alpha 1- and alpha 2-adrenoceptor binding. Eur J Pharmacol 1986;125: 373–81.
- Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856–65.
- Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63:920–30.
- Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001;24:59–73.
- Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466–76.
- World Health Organization. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. Geneva: World Health Organization; 1993.
- Clinical Global Impression (CGI). In: Guy W, editor. ECDEU. Assessment manual for psychopharmacology (revised). Rockville, MD: US Department of Health, Education and Welfare, NINH;1976. p. 218–22
- Simpson GM, Angus JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatr Scand (Suppl) 1970;212:11–25.
- Tazari Fl, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001;297:711–7.
- Herran A, Garcia-Unzueta MT, Amado JA, de La Maza MT, Alvarez C, Vazquez-Barquero JL. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 2001; 179:560–1.